Short- and long-term effects of semaglutide [amount hidden] on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

These brief studies could not assess whether semaglutide has long-term effects on eating that support the maintenance of lost weight.

Who Took Part

The abstract describes 120 adults taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In laboratory assessments at weeks 0, 20, 40, and 60, participants rated their appetite when fasting and for 4 h after a standardized breakfast.

Missing data were estimated using jump-to-reference multiple imputation, and analyses of covariance compared the groups in change at each assessment, controlling for baseline.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Semaglutide and who got the comparison, which limits bias.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

Energy intake was measured during an ad libitum lunch.

Measures of food reward included the Power of Food Scale.

What Was Measured

These brief studies could not assess whether semaglutide has long-term effects on eating that support the maintenance of lost weight.

Topics PubMed links to this paper include Appetite, Energy Intake, Obesity, Overweight, Reward, Semaglutide and Weight Loss.

Author keywords: antiobesity medications, dietary intake, eating behaviors, glucagon-like peptide receptor agonists (GLP-1RAs) and obesity management.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 120 adults.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (The American journal of clinical nutrition), a journal based in United States.

More context: the Semaglutide compound page, all human trials.